BD Veritor System for SARS-CoV-2
BD Diagnostic Solutions / Becton, Dickinson & Company · Decision date Oct 27, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision for BD Veritor System for SARS-CoV-2, 510(k) number K261379, on 2026-10-27. The applicant is BD Diagnostic Solutions / Becton, Dickinson & Company of Sparks, MD. The submission was received 04/27/2026, falls under product code QVF and the Microbiology review panel, and was not reviewed by a third party.
SESE means the device was cleared as substantially equivalent to a predicate; it is not a PMA approval. The public record lists the classification name as a simple point-of-care device to directly detect SARS-CoV-2 viral targets from clinical specimens in near-patient settings. The page does not state which components or changes were assessed, the predicate device, or any performance data, so the scope of this clearance remains unknown from the cited record.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Microbiology
- Decision date
- Oct 27, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K261379
- Regulatory pathway
- 510(k) premarket notification
- Product code
- QVF
- Decision code
- SESE
- Decision date
- Oct 27, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Simple Point-Of-Care Device To Directly Detect Sars-Cov-2 Viral Targets From Clinical Specimens In Near-Patient Settings.
- Product code
- QVF
- FDA device class
- 2
FDA decision timeline
K261379 received
Application receipt date recorded by FDA.
K261379 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code QVF
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Ortho Clinical Diagnostics Inc. (QuidelOrtho) | 510(k) clearance | Sep 4, 2026 | FDA | |
| CorDx, Inc. | 510(k) clearance | Jun 1, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
BD Diagnostic Solutions / Becton, Dickinson & Company
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Sparks, MD
Sources and methodology
- Original FDA record: K261379
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
